Major Investor Discloses 9.56% Stake in Celularity Inc. Following $10M Secured Financing and Board Observer Right
CELU sits 32% above its 52-week low of $1.01 on light trading volume (0.1× avg).
Summary
A family trust has disclosed a 9.56% beneficial ownership stake in Celularity Inc. following a $10 million financing deal in December 2025, which included senior secured and convertible notes, warrants, and a board observer right.
Key Events · Ownership and Investor Activity · CELU
-
Significant Beneficial Ownership Disclosed
The Philip & Daniele Barach Family Trust, along with its trustees, reported beneficial ownership of 3,012,048 shares, representing 9.56% of Celularity Inc.'s Class A Common Stock. This calculation assumes the conversion of $5 million in convertible notes, including potential additional tranches.
-
$10 Million Secured Financing Completed
The ownership stems from a $10 million financing transaction on December 19, 2025, comprising a $7 million senior secured promissory note and a $3 million convertible secured promissory note. The Trust also has the right to purchase an additional $2 million in convertible notes.
-
Warrants Issued to Investor
In connection with the financing, the Trust received five-year warrants to purchase 3,707,457 shares of Class A Common Stock at an exercise price of $2.00 per share, exercisable from June 19, 2026.
-
Board Observer Right Granted
The Trust was granted the right to designate a non-voting observer, Philip Barach, to attend meetings of the Company's Board of Directors, indicating significant investor influence.
Analysis · CELU · Life Sciences
This Schedule 13D filing reveals that the Philip & Daniele Barach Family Trust has become a significant shareholder in Celularity Inc., holding a 9.56% beneficial stake. This ownership results from a substantial $10 million financing package provided to the company in December 2025, which included secured notes and warrants. For a company with a market capitalization of approximately $38 million, this capital infusion is material and likely critical for extending its operational runway. The conversion price of the convertible notes ($1.66) is above the current stock price ($1.33), which is a positive indicator for the terms of the financing. However, the warrants are currently out-of-the-money. The granting of a board observer right to the Trust signifies a notable level of influence for this investor, suggesting they will play an active role in the company's strategic direction. Investors should monitor any future actions or proposals from the Barach Family Trust, as their significant stake and board access could lead to corporate governance or strategic changes.
At the time of this filing, CELU was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.4M. The 52-week trading range was $1.01 to $4.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.